Pdf background in patients with heart failure, betablochade has improved morbidity and leftventricular function, but the impact on survival is. Apr 01, 2008 heart failure caused by systolic dysfunction affects more than 5 million adults in the united states and is a common source of outpatient visits to primary care physicians. The mean age of patients in the study was 73 years and 38% were women. Cibis iii was an investigatorinitiated, multicenter trial that compared the effects on mortality and hospitalization of initial monotherapy with either bisoprolol or enalapril for 6 months. Pooling of total mortality data by sex and overall from cibis ii,2 merithf,3 and copernicus5 was performed with a metaanalysis technique based on the 95% cis of the relative risks in the studies. A randomized trial of betablockade in heart failure. Only 219 patients 25% achieved smooth titration to the target dose without the need to delay increases or reduce the dose. The journal of family practice, 7 century drive, suite 302, parsippany, nj 07054 we want to hear from you. Data for total hospitalizations are shown in table ii. In these women it reduces their risk of developing a new cancer in the opposite contralateral breast by 53% compared to tamoxifen 1.
Release randomized intervention trial in heart failure merit. We aim to provide an overview of the conventional single photon emission computed tomography spect and emerging positron emission tomography pet catecholamine analogue tracers for assessing myocardial nerve integrity, in particular focusing on 18flabeled tracers. In race ii trial, goal resting hr jan 28, 2009 recently, the carvedilol or metoprolol european trial comet, 8 a double. Background underrepresentation of women in hf clinical trials has limited our understanding of genderrelated differences in patients with hf. Mar 29, 2011 heart failure is a major public health concern that is frequently complicated by ventricular arrhythmias. Therapeutic interchange of carvedilol to bisoprolol for.
Treatment of ventricular tachycardia in patients with heart. Pharmacologic management of heart failure caused by. Sustained ventricular tachycardia is associated with an increased risk for progressive heart failure and sudden death. Simon, md, march 2001, and simon et al10 with epiinfo version 6. Metoprolol crxl in female patients with heart failure. The first of these trials is the cardiac insufficiency bisoprolol study cibis i. We summarize the current management strategies for ventricular tachycardia in heart failure patients, including implantable cardioverterdefibrillator therapy. The merithf trial demonstrated that treatment with metoprolol crxl resulted in. Clinical trials update from the esc heart failure meeting 2009. The safety of amiodarone in patients with heart failure. Increasingly, the cardiac sympathetic nervous system sns is being.
Metoprolol tartrate pharmacokinetics absorption bioavailability. Baseline heart rate was higher in the carvedilol group 822 bpm vs. What is the best betablocker mountain area health for. Based on recommended initial starting and target doses of these 2 betablockers in the various clinical trials cibis ii, us carvedilol studies, 12 and copernicus, 11 and the clinical pharmacy practice guidelines for hf patients developed by singapore ministry of health, 7 we decided on a 5. The cardiac insufficiency bisoprolol study ii cibis ii. Pdf the cardiac insuffiency bisoprolol study ii cibis ii. Objectives the goal of this study was to determine the influence of gender on baseline characteristics, response to treatment, and prognosis in patients with heart failure hf and impaired left ventricular ejection fraction lvef. Followup at 12 years p hase ii trials of bblockers,typically lasting 3 to 6 months, demonstrated that bblocker treatment in patients with heart failure hf results in improvements in right heart hemodynamics, reversal of ventricular remodeling as evidenced by reductions in left. Parepet is a prospective, observational cohort study funded by nhlbi. In cibis ii, which was a doubleblind trial that randomized 2647 patients with symptomatic nyha class iii or iv hf and lvef. Controversies in the use of beta blockers in heart failure. Ibis ii was designed to continue the work started in ibisi by examining the role of anastrozole in the prevention of breast cancer which we hope will reduce breast cancer by even more than tamoxifen with less serious side effects. Background underrepresentation of women in hf clinical trials has limited our understanding of genderrelated differences in patients with. New heart failure clinical trials 19981101 ahc media.
The trial was stopped prematurely at the second interim analysis because of positive results in the beta blocker arm. Interpretation of these data is the responsibility of the authors, and in no way should be seen as an official policy or interpretation of the u. Merithf and cibis ii trials, the placebo mortality rate and the mortality risk reduction of metoprolol and bisoprolol are similar to that achieved by carvedilol in copernicus. Cibis ii was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. Heart failure caused by systolic dysfunction affects more than 5 million adults in the united states and is a common source of outpatient visits to primary care physicians. Ekman m, zethraeus n, jonsson b 2001 cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in sweden. Trial of s1 maintenance therapy in metastatic esophagogastric cancer mateo the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The trial system delivers the same therapy provided by the implanted device, allowing you. New heart failure clinical trial 19981129 ahc media. Metoprolol tartrate is rapidly and almost completely absorbed from the gi tract. Usrds waves 3 and 4 study11the data reported here were supplied by the united states renal data system. The results of cibis ii were reported at the second annual scientific meeting of the heart failure society of america that should influence physician practice in the care of patients with left ventricular dysfunction and heart failure.
This was the main objective of the cardiac insufficiency bisoprolol study cibis. Allcause mortalityallcause hospitalisationssuddendeath. Listing a study does not mean it has been evaluated by the u. This study aimed to analyze the degree of concordance between targeted cibis ii. The cardiac insufficiency bisoprolol study ii cibisii. This website is a free of charge service from daiichi sankyo europe gmbh. Betaadrenergic blocker mortality trials in congestive heart failure. A comparative analysis of the results from 4 trials of. The cardiac insufficiency bisoprolol study cibisii which was a randomized trial of hf patients with left ventricular ejection fraction. Methods the study design and protocol of cibis has been published. The benefits of beta blockers in heart failure are highly dependent on dosage. The mortality benefit of lowdose beta blockade in congestive heart failure is encouraging.
Nyha class iii and iv hf patients n2,647 with lvef cibis ii study to evaluate bisoprolol for allcause mortality. Total heart failure direct costs were estimated as part of a threestep process. It is designed to determine whether hibernating myocardium andor inhomogeneity of sympathetic innervation by positron emission tomography imaging identifies patients with ischemic cardiomyopathy who are at high risk for scd and cardiovascular mortality. Ibis ii prevention research has shown that anastrozole is more effective than tamoxifen in preventing the return of cancer in postmenopausal women who have an early breast cancer removed. Selective versus nonselective adrenergic receptor blockade. Colucci ws, packer m, bristow mr et al, for the us carvedilol heart failure study group. A free powerpoint ppt presentation displayed as a flash slide show on id. Bisoprolol doseresponse relationship in patients with congestive heart failure.
All patients had new york heart association functional class ii or iii symptoms. Prediction of arrhythmic events with positron emission. Impact of a standardized heart failure order set on mortality. Cibis ii results will represent a basis for definite conclusions on the evaluation of betaadrenoceptor blockade induced benefit with bisoprolol in chronic heart failure. All decisions regarding this manuscript were made by a guest editor. Les betabloqueurs dans linsuffisance cardiaque revue medicale. Bisoprolol doseresponse relationship in patients with congestive. Management of hypertension alone or in combination with other classes of antihypertensive agents. Hf, the cardiac insufficiency bisoprolol study ii cibis. Cibisii was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit.
Listing a study does not mean it has been evaluated by. Allcause mortality was significantly lower with bisoprolol than on placebo 156 11. Eula suiteplus trial for sql server 2008, 2012, 2014, 2016. Functional benefit in heart failure due to idiopathic dilated cardiomyopathy has been observed after betablockade, but improvement in survival has not been established in a largescale randomized trial. Pharmacologic management of heart failure caused by systolic. There were no other significant differences in baseline systemic or pulmonary hemodynamics between the two groups. Reply journal of the american college of cardiology.
745 976 1619 612 317 159 1192 472 154 1648 668 1321 1403 269 82 1173 208 1462 554 1052 1482 1303 676 1494 1118 801 904 50 469 97 899 372 264